ClinicalTrials.gg
CompletedNCT07547774Updated Nov 17, 2026

Preoperative Sleep Quality and Postoperative Outcomes in Breast Surgery

An observational study in Breast Cancer, Postoperative Pain and Inflammation, sponsored by Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital. Completed at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital · Observational

How we know

Updated Nov 17, 2026Now CompletedPrimary completion moved+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
156
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 400 studies in Breast Neoplasms with a site in Turkey — 83 open to participants now, 129 under way, 46 of them phase 3. Breast Neoplasms · Turkey.

Enrollment
21st of 79
156 · median 80
Started
2026
with 39 others
Observational
79 of 400
15 open now
Registered
367th of 400
by date

Among the 400 studies in Breast Neoplasms with a site in Turkey, this one is the 21st largest by enrollment of the 79 observational ones that give a count, is one of 40 that started in 2026, is one of 79 observational ones, and was the 367th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

83 of the 400 studies in Breast Neoplasms with a site in Turkey are open now. Recruiting first, the newest first:

78 more — sign in →

All 83 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 400 studies in Breast Neoplasms with a site in Turkey, or all of them as a file.
02

Study summary

This prospective, single-center observational study examined the association between preoperative sleep quality and postoperative outcomes in women undergoing elective breast cancer surgery. Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI), with scores ≤5 indicating good sleep quality and scores >5 indicating poor sleep quality.

The primary outcome was the systemic immune-inflammation index (SII), calculated from routine blood counts obtained 24 hours after surgery. Postoperative SII was compared between sleep-quality groups, accounting for preoperative SII and relevant clinical and surgical characteristics. Secondary outcomes included change in SII from baseline, pain intensity during the first 45 minutes in the post-anesthesia care unit (PACU), opioid consumption, rescue analgesic requirement, and length of hospital stay. Pain was assessed using a 10-cm visual analogue scale on PACU arrival and at 15, 30, and 45 minutes. Opioid consumption included morphine and tramadol administered during the final 20 minutes of surgery and the first 45 minutes in the PACU, expressed as intravenous morphine equivalents.

No treatment was assigned by the study protocol. Anesthetic and analgesic management followed routine clinical practice.

Read the detailed description

This prospective observational study was conducted at Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital in Ankara, Turkey, among women undergoing elective breast cancer surgery under general anesthesia. Procedures included lumpectomy or mastectomy, with axillary dissection when clinically indicated. The study examined whether preoperative sleep quality was associated with postoperative systemic immune-inflammation index (SII), immediate postoperative pain, and analgesic use.

Preoperative sleep quality was assessed using the validated Turkish version of the Pittsburgh Sleep Quality Index (PSQI). The total score ranges from 0 to 21, with higher scores indicating poorer sleep quality. Patients were classified as having good sleep quality (PSQI ≤5) or poor sleep quality (PSQI >5). Demographic characteristics, comorbidities, oncological history, surgical characteristics, and perioperative clinical data were recorded prospectively.

The primary outcome was SII measured 24 hours (±6 hours) after surgery, calculated as platelet count × neutrophil count / lymphocyte count. Preoperative SII was calculated using the same formula. The primary analysis compared postoperative SII between sleep-quality groups, adjusting for baseline SII and clinical and surgical covariates. Change in SII, calculated as postoperative minus preoperative SII, was a secondary outcome.

Pain intensity was assessed using a 10-cm visual analogue scale (VAS), anchored at "no pain" and "worst imaginable pain." Patients marked their pain intensity on the line; the distance from the zero anchor was measured and rounded to the nearest whole centimeter. Assessments were performed on arrival in the post-anesthesia care unit (PACU) and at 15, 30, and 45 minutes. Maximum VAS was defined as the highest score across the four scheduled assessments. The pain assessor was unaware of patients' PSQI scores and sleep-quality groups.

Anesthetic and analgesic management followed routine clinical practice, with no treatment assigned by the study protocol. Intravenous morphine or tramadol was administered for postoperative analgesia during the final 20 minutes of surgery. Rescue analgesia consisted of intravenous morphine or tramadol when the PACU VAS score was ≥4; drug selection and dosing were determined by the treating anesthesiologist. Scheduled pain assessments continued after rescue treatment. No regional blocks or surgical local anesthetic infiltration were performed.

Total opioid consumption comprised morphine and tramadol administered during the final 20 minutes of surgery and the first 45 minutes in the PACU. Intravenous tramadol doses were converted to intravenous morphine equivalents using a factor of 0.1 and added to the administered morphine dose. Fentanyl used for induction and remifentanil used for maintenance were excluded from this measure. Rescue analgesic requirement was defined as receipt of at least one rescue opioid dose during the PACU observation period. The planned 24-hour pain and opioid outcomes could not be reliably evaluated because of follow-up limitations and incomplete opioid documentation. The reported analyses were therefore restricted to PACU pain during the first 45 minutes and opioid administration during the final 20 minutes of surgery and this PACU period. Length of hospital stay was also recorded.

Secondary analyses evaluated PSQI total score as a continuous predictor of postoperative SII, maximum VAS, total opioid consumption, and rescue analgesic requirement. Adjustment variables included age, body mass index, ASA physical status III, chronic disease burden, chemotherapy within the previous year, axillary dissection, and operation duration. Breast surgery type was added to the models during manuscript revision. Preoperative SII was included only in the postoperative SII models. Individual covariate-outcome associations were interpreted as exploratory.

03

Conditions studied

  • Breast Cancer
  • Postoperative Pain
  • Inflammation
04

Who can participate

The criteria were revised on the registry on Oct 21, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population included women aged 18-75 years who underwent elective breast cancer surgery at a tertiary oncology center. Procedures included breast-conserving surgery (lumpectomy) or mastectomy, with or without axillary dissection. Preoperative sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI). All patients received routine perioperative care, and no treatment was assigned by the study protocol. This observational study examined the association between preoperative sleep quality and postoperative outcomes in routine clinical practice.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients aged 18 to 75 years
  • Scheduled for elective breast cancer surgery
  • (ASA) physical status I to III
  • Able to understand and complete the Pittsburgh Sleep Quality Index (PSQI)
  • Willing to participate in the study
  • Provided written

Exclusion criteria

Exclusion Criteria:

  • Active infection
  • History of chronic inflammatory disease or disease
  • Use of or drugs within the past 6 months
  • Known diagnosis of obstructive sleep apnea syndrome
  • Severe cognitive impairment preventing completion of the questionnaire
  • Planned emergency surgery
  • Refusal to participate or failure to provide
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
156 participants (actual)
Patient registry
No

Groups and cohorts

  • Good Sleep Quality (PSQI ≤ 5)

    Patients with good preoperative sleep quality, defined as a Pittsburgh Sleep Quality Index (PSQI) score ≤5, were included in this cohort. Sleep quality was assessed preoperatively using the validated PSQI questionnaire. No treatment was assigned by the study protocol, and patients received routine perioperative care. Postoperative SII, pain intensity, and analgesic consumption were compared with those in the poor-sleep-quality group.

    Other: Preoperative Sleep Quality Assessment (PSQI)

  • Poor Sleep Quality (PSQI > 5)

    Patients with poor preoperative sleep quality, defined as a Pittsburgh Sleep Quality Index (PSQI) score \>5, were included in this cohort. Sleep quality was assessed preoperatively using the validated PSQI questionnaire. No treatment was assigned by the study protocol, and patients received routine perioperative care. Postoperative SII, pain intensity, and analgesic consumption were compared with those in the good-sleep-quality group.

    Other: Preoperative Sleep Quality Assessment (PSQI)

Interventions

  • OtherPreoperative Sleep Quality Assessment (PSQI)

    Preoperative sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI), a validated self-reported questionnaire covering the preceding month. Patients were classified into two cohorts: good sleep quality (PSQI ≤5) and poor sleep quality (PSQI \>5). The PSQI assessment was used for grouping and analysis. No treatment was assigned by the study protocol, and perioperative management followed routine clinical practice.

    Also known as: Pittsburgh Sleep Quality Index (PSQI)

06

What researchers measure

Primary outcomes

  1. Postoperative Systemic Immune-Inflammation Index (SII)

    The primary outcome was the postoperative systemic immune-inflammation index (SII), calculated from routine complete blood count measurements obtained 24 hours after surgery. SII was calculated using the formula: platelet count × neutrophil count / lymphocyte count. Postoperative SII was compared between patients with poor (PSQI \>5) and good (PSQI ≤5) preoperative sleep quality, adjusting for preoperative SII and clinical and surgical covariates.

    Time frame: At 24 hours postoperatively (± 6 hours)

Secondary outcomes

  1. Change in Systemic Immune-Inflammation Index (ΔSII)

    Change in SII was calculated as postoperative SII minus preoperative SII. SII was calculated at both time points as platelet count × neutrophil count / lymphocyte count. Changes were compared between patients with good (PSQI ≤5) and poor (PSQI \>5) preoperative sleep quality.

    Time frame: From the preoperative assessment to 24 hours after surgery.

  2. Immediate Postoperative Pain Intensity

    Pain intensity was assessed using a 10-cm visual analogue scale (VAS), anchored at 0 cm ("no pain") and 10 cm ("worst imaginable pain"). Patients marked their pain intensity on the line, and the measured distance was rounded to the nearest whole centimeter. Scores were recorded at each scheduled assessment, including after rescue analgesia when applicable. Maximum VAS was defined as the highest score across the four assessments

    Time frame: On arrival in the post-anesthesia care unit (0 minutes) and at 15, 30, and 45 minutes after arrival.

  3. Total Opioid Consumption for Postoperative Analgesia

    Total opioid consumption was calculated as the sum of intravenous morphine and tramadol administered for postoperative analgesia during the final 20 minutes of surgery and the first 45 minutes in the post-anesthesia care unit (PACU), including rescue doses. Tramadol doses were multiplied by 0.1 to obtain intravenous morphine equivalents and added to the morphine dose. Consumption was expressed in milligrams of intravenous morphine equivalents. Fentanyl administered during induction and remifentanil used for maintenance were excluded.

    Time frame: From 20 minutes before the end of surgery through the first 45 minutes after PACU arrival.

  4. Rescue Analgesic Requirement

    Rescue analgesic requirement was defined as receipt of at least one intravenous dose of morphine or tramadol during the first 45 minutes in the post-anesthesia care unit (PACU). Rescue analgesia was administered when the visual analogue scale (VAS) score was ≥4. Drug selection and dosing were determined by the anesthesiologist responsible for PACU care. The outcome was recorded as yes/no and summarized as the number and percentage of patients receiving rescue analgesia.

    Time frame: Within the first 45 minutes after arrival in the post-anesthesia care unit.

  5. Postoperative Length of Hospital Stay

    Postoperative length of hospital stay was defined as the duration from the day of breast cancer surgery to hospital discharge, measured in days.

    Time frame: From the date of surgery until hospital discharge, assessed up to 15 days after surgery.

07

Study locations

1 site
  • Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital Clinic of Anesthesiology and Reanimation
    Ankara, 06200, Turkey (Türkiye)
08

References and documents

Publications

  • Irwin MR. Why sleep is important for health: a psychoneuroimmunology perspective. Annu Rev Psychol. 2015 Jan 3;66:143-72. doi: 10.1146/annurev-psych-010213-115205. Epub 2014 Jul 21. PubMed 25061767 ↗
  • Haack M, Simpson N, Sethna N, Kaur S, Mullington J. Sleep deficiency and chronic pain: potential underlying mechanisms and clinical implications. Neuropsychopharmacology. 2020 Jan;45(1):205-216. doi: 10.1038/s41386-019-0439-z. Epub 2019 Jun 17. PubMed 31207606 ↗
  • Finan PH, Goodin BR, Smith MT. The association of sleep and pain: an update and a path forward. J Pain. 2013 Dec;14(12):1539-52. doi: 10.1016/j.jpain.2013.08.007. PubMed 24290442 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared. The study involves sensitive clinical data collected from patients in a single-center setting, and data sharing is restricted in order to protect patient confidentiality and comply with institutional and ethical regulations. De-identified and aggregated data may be available from the corresponding author upon reasonable request, subject to approval by the institutional ethics committee.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2026 to primary completion in Aug 2026, 4 months.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's 4 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

Primary completion moved twice since we started tracking on Sep 25, 2026: Jul 2026 → Aug 2026, last on Nov 17, 2026.

Completion moved twice since we started tracking on Sep 25, 2026: Jul 2026 → Aug 2026, last on Nov 17, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2026
First posted
Apr 23, 2026
StartActual
Apr 17, 2026
Primary completionActual
Aug 20, 2026was Jul 2026
CompletionActual
Aug 30, 2026was Jul 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 21, 2026
Sites
1 site added, 1 site removed
Show site
  • Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital Clinic of Anesthesiology and Reanimation · Ankara, Turkey (Türkiye)
Show 1 removed
  • Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital Clinic of Anesthesiology and Rea · Ankara, Turkey (Türkiye)
Nov 17, 2026
Start date
Apr 1, 2026→Apr 17, 2026
Oct 21, 2026
Primary completion
Jul 1, 2026→Aug 20, 2026
moved 2 times, Oct 21, 2026 – Nov 17, 2026
Study completion
Jul 15, 2026→Aug 30, 2026
moved 2 times, Oct 21, 2026 – Nov 17, 2026
Enrollment
150 (estimated)→156
Nov 17, 2026
Eligibility
Maximum age 70 Years→75 Years; 1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedFemale patients aged 18 to 7075 years
across 2 updates, Oct 21, 2026 – Nov 17, 2026
Primary outcomes
Revised in 2 updates
What changed on Oct 21, 2026
  • EditedPostoperative Systemic Inflammatory ResponseImmune-Inflammation Index (SII)Time frame: At 24 hours postoperatively (± 6 hours)
What changed on Nov 17, 2026
  • DescriptionPostoperative Systemic Immune-Inflammation Index (SII): how it is measured was reworded
across 2 updates, Oct 21, 2026 – Nov 17, 2026
Secondary outcomes
Revised in 2 updates
What changed on Oct 21, 2026
  • AddedImmediate Postoperative Pain IntensityTime frame: On arrival in the post-anesthesia care unit (0 minutes) and at 15, 30, and 45 minutes after arrival.
  • AddedTotal Opioid Consumption for Postoperative AnalgesiaTime frame: From 20 minutes before the end of surgery through the first 45 minutes after PACU arrival.
  • RemovedPostoperative Pain Intensity (Visual Analog Scale, VAS)Time frame: At 2, 6, 12, and 24 hours postoperatively.
  • RemovedTotal Postoperative Analgesic ConsumptionTime frame: Cumulative dose within the first 24 hours postoperatively
  • Time frameChange in Systemic Immune-Inflammation Index (ΔSII)From preoperative baseline to 24 hours postoperatively → From the preoperative assessment to 24 hours after surgery.
  • DescriptionChange in Systemic Immune-Inflammation Index (ΔSII): how it is measured was reworded
What changed on Nov 17, 2026
  • AddedRescue Analgesic RequirementTime frame: Within the first 45 minutes after arrival in the post-anesthesia care unit.
  • AddedPostoperative Length of Hospital StayTime frame: From the date of surgery until hospital discharge, assessed up to 15 days after surgery.
across 2 updates, Oct 21, 2026 – Nov 17, 2026
Show all 2 updates
  1. Nov 17, 2026
    1 site added, 1 site removed
    Show site
    • Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital Clinic of Anesthesiology and Reanimation · Ankara, Turkey (Türkiye)
    Show 1 removed
    • Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital Clinic of Anesthesiology and Rea · Ankara, Turkey (Türkiye)
    Primary completion Sep 1, 2026→Aug 20, 2026
    Study completion Oct 1, 2026→Aug 30, 2026
    Enrollment 128→156
    Eligibility Revised
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionPostoperative Systemic Immune-Inflammation Index (SII): how it is measured was reworded
    Secondary outcomes 2 added
    What changed in the outcomes
    • AddedRescue Analgesic RequirementTime frame: Within the first 45 minutes after arrival in the post-anesthesia care unit.
    • AddedPostoperative Length of Hospital StayTime frame: From the date of surgery until hospital discharge, assessed up to 15 days after surgery.
    + 3 other changes: verification date, description and arm descriptions
  2. Oct 21, 2026
    Recruiting→Completed
    Start date Apr 1, 2026→Apr 17, 2026
    Primary completion Jul 1, 2026→Sep 1, 2026 (now actual)
    Study completion Jul 15, 2026→Oct 1, 2026 (now actual)
    Enrollment 150 (estimated)→128 (actual)
    Eligibility Maximum age 70 Years→75 Years; 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedFemale patients aged 18 to 7075 years
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedPostoperative Systemic Inflammatory ResponseImmune-Inflammation Index (SII)Time frame: At 24 hours postoperatively (± 6 hours)
    Secondary outcomes 1 time frame changed, 2 added, 2 removed, 1 description edited
    What changed in the outcomes
    • AddedImmediate Postoperative Pain IntensityTime frame: On arrival in the post-anesthesia care unit (0 minutes) and at 15, 30, and 45 minutes after arrival.
    • AddedTotal Opioid Consumption for Postoperative AnalgesiaTime frame: From 20 minutes before the end of surgery through the first 45 minutes after PACU arrival.
    • RemovedPostoperative Pain Intensity (Visual Analog Scale, VAS)Time frame: At 2, 6, 12, and 24 hours postoperatively.
    • RemovedTotal Postoperative Analgesic ConsumptionTime frame: Cumulative dose within the first 24 hours postoperatively
    • Time frameChange in Systemic Immune-Inflammation Index (ΔSII)From preoperative baseline to 24 hours postoperatively → From the preoperative assessment to 24 hours after surgery.
    • DescriptionChange in Systemic Immune-Inflammation Index (ΔSII): how it is measured was reworded
    + 5 other changes: identifiers, verification date, description, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07547774
Lead sponsor
Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
Responsible party
Mustafa Kemal ŞAHİN (M.D, Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital) — Principal investigator
First posted
Apr 23, 2026
Start date
Apr 17, 2026
Primary completion
Aug 20, 2026
Completion
Aug 30, 2026
Last update
Nov 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion